{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390564227338918656.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.15369/sujms.31.253"}},{"identifier":{"@type":"URI","@value":"http://id.nii.ac.jp/1670/00003036/"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/sujms/31/3/31_253/_pdf"}},{"identifier":{"@type":"NAID","@value":"130007742532"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2020268899"}}],"resourceType":"紀要論文(departmental bulletin paper)","dc:title":[{"@language":"en","@value":"Persistence of Cryoglobulinemia in Patients with Chronic Hepatitis C after Successful Treatment with Direct-acting Antivirals"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"Hepatitis C virus（HCV）infection can cause chronic liver disease; it has also been associated with lymphoproliferative disorders（LPDs）, such as cryoglobulinemia and B-cell non-Hodgkin’s lymphoma.  Our previous studies suggested that cryoglobulinemia, high titer of rheumatoid factor（RF）, and hypocomplementemia are immunological markers of LPDs.  In addition, recent therapies with direct-acting antivirals（DAAs）have achieved high rates of sustained virological response（SVR）in patients with chronic hepatitis C（CH-C）.  This study analyzed the efficacy of DAA therapy in CH-C patients with cryoglobulinemia, and the association of biochemical and other immune markers for LPDs with persistence of cryoglobulinemia in patients after DAA therapy.  Of 226 patients tested, 31（13.7％）had cryoglobulinemia prior to receiving DAAs, and these individuals showed lower complement 4 levels, decreased complement hemolytic activity, and higher IgM than patients without cryoglobulinemia.  Of the 24 cryoglobulinemia-positive patients（83％）who could be followed for 24 weeks, 20 became cryoglobulinemia negative after the therapy.  The remaining four patients retained the abnormal LPD markers, indicating the possibility of long-term LPD persistence even following successful eradication of HCV in CH-C patients.  Thus, long-term follow-up is recommended to avoid exacerbation of extrahepatic manifestations as well as new events."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410564227338918665","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852860"}],"foaf:name":[{"@language":"en","@value":"NAKAJIMA Yoko"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918662","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852867"}],"foaf:name":[{"@language":"en","@value":"UCHIKOSHI Manabu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918658","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852868"}],"foaf:name":[{"@language":"en","@value":"WANG Tianpeng"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918272","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852869"}],"foaf:name":[{"@language":"en","@value":"SUGIURA Ikuya"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918667","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852870"}],"foaf:name":[{"@language":"en","@value":"KAJIWARA Atsushi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918657","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852871"}],"foaf:name":[{"@language":"en","@value":"ARAI Jun"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918663","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852872"}],"foaf:name":[{"@language":"en","@value":"UOZUMI Shojiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918661","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852873"}],"foaf:name":[{"@language":"en","@value":"SHIMOZUMA Yuu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918660","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852874"}],"foaf:name":[{"@language":"en","@value":"SAKAKI Masashi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918666","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852861"}],"foaf:name":[{"@language":"en","@value":"NOMURA Norihiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Digestive Diseases Center, Showa University Koto Toyosu Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918664","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852862"}],"foaf:name":[{"@language":"en","@value":"EGUCHI Junichi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Digestive Diseases Center, Showa University Koto Toyosu Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918274","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852863"}],"foaf:name":[{"@language":"en","@value":"NOZAWA Hisako"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918273","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852864"}],"foaf:name":[{"@language":"en","@value":"KURIHARA Toshikazu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Internal Medicine, Showa University Karasuyama Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918656","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852865"}],"foaf:name":[{"@language":"en","@value":"ITO Takayoshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Digestive Diseases Center, Showa University Koto Toyosu Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410564227338918659","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000404852866"}],"foaf:name":[{"@language":"en","@value":"YOSHIDA Hitoshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09156380"},{"@type":"EISSN","@value":"21850968"},{"@type":"ISSN","@value":"09156380"},{"@type":"NCID","@value":"AA10781651"}],"prism:publicationName":[{"@language":"en","@value":"The Showa University Journal of Medical Sciences"},{"@language":"ja","@value":"Ｔｈｅ　Ｓｈｏｗａ　Ｕｎｉｖｅｒｓｉｔｙ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃａｌ　Ｓｃｉｅｎｃｅｓ"},{"@language":"en","@value":"Showa Univ J Med Sci"},{"@language":"en","@value":"The Showa University Journal of Medical Sciences"},{"@language":"en","@value":"Showa. Univ. J. Med. Sci."},{"@language":"ja","@value":"Ｔｈｅ　Ｓｈｏｗａ　Ｕｎｉｖｅｒｓｉｔｙ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃａｌ　Ｓｃｉｅｎｃｅｓ"}],"dc:publisher":[{"@language":"en","@value":"The Showa University Society"},{"@language":"ja","@value":"昭和大学学士会"}],"prism:publicationDate":"2019","prism:volume":"31","prism:number":"3","prism:startingPage":"253","prism:endingPage":"262"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://id.nii.ac.jp/1670/00003036/"},{"@id":"https://www.jstage.jst.go.jp/article/sujms/31/3/31_253/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2020268899"}],"availableAt":"2019","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=cryoglobulinemia","dc:title":"cryoglobulinemia"},{"@id":"https://cir.nii.ac.jp/all?q=HCV","dc:title":"HCV"},{"@id":"https://cir.nii.ac.jp/all?q=DAA","dc:title":"DAA"},{"@id":"https://cir.nii.ac.jp/all?q=lymphoproliferative%20disorders","dc:title":"lymphoproliferative disorders"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235581379584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lymphotropic hepatitis C virus has an interferon‐resistant phenotype"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011143783325312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618627961984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis C virus infection in patients with non‐Hodgkin's lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619154920064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to α-interferon therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568855938944","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045301597568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A clinical and virological study of hepatitis C virus-related cryoglobulinemia in Germany"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519478444288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis C: The clinical spectrum of disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520202659456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993836543104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Natural history of hepatitis C"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995975145472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis C virus induces a mutator phenotype: Enhanced mutations of immunoglobulin and protooncogenes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469473527040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945034987776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct-Acting Antivirals"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945597333888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946262259456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419052661888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Interferon Alfa-2a Therapy in Cryoglobulinemia Associated with Hepatitis C Virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419468280704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419895165696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extrahepatic manifestations of HCV infection: facts and controversies"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420348745472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420883524480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antibodies against hepatitis C virus in mixed cryoglobulinemia patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421104479360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Outcomes after Transfusion-Associated Hepatitis C"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894670412800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extrahepatic manifestations of chronic hepatitis C"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369623684864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis C Virus Infection in Patients with Essential Mixed Cryoglobulinemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370162212864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Role for Hepatitis C Virus Infection in Type II Cryoglobulinemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370398249728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"T(14;18) translocation in chronic hepatitis C virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370570872960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845271905792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845769658112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793334393472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extrahepatic Morbidity and Mortality of Chronic Hepatitis C"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794704665600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Characterization of Pseudotype VSV Possessing HCV Envelope Proteins"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796079342592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Therapy for Hepatitis C Virus–Related Cryoglobulinemic Vasculitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796223118720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270092610432","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271280717312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2007503996"},{"@type":"IRDB","@value":"oai:irdb.nii.ac.jp:00976:0004318857"},{"@type":"CROSSREF","@value":"10.15369/sujms.31.253"},{"@type":"CIA","@value":"130007742532"},{"@type":"OPENAIRE","@value":"doi_dedup___::a47ce984ae5cbbe6e7c601f49cda97d4"}]}